Tech Company Financing Transactions
Prelude Therapeutics Funding Round
Prelude Therapeutics closed a $50 million Series C funding round on 8/25/2020. Backers included Fidelity Management & Research Company, OrbiMed and private investors.
Transaction Overview
Company Name
Announced On
8/25/2020
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
Fidelity Management & Research Company (Lead Investor)
OrbiMed (Lead Investor)
Proceeds Purpose
With proceeds from this financing, we believe we are well positioned to continue to execute on building and advancing our pipeline of therapies designed to target key drivers of cancer cell growth, survival and resistance to existing treatments.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Powder Mill Rd.
Wilmington, DE 19803
USA
Wilmington, DE 19803
USA
Phone
Website
Email Address
Overview
Prelude (Nasdaq: PRLD) was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with experience in developing cancer medicines to create a next generation cancer drug discovery company.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kris Vaddi
Chief Financial Officer
Brian Piper
Chief Medical Officer
David Mauro
Chief Scientific Officer
Peggy Scherle
Executive Vice President
Andrew Combs
Vice President
Madhu Pudipeddi
VP - R & D
Aimee Crombie
VP - Regulatory Affairs
Adam Shilling
Browse more venture capital transactions:
Prev: 8/25/2020: Shef venture capital transaction
Next: 8/25/2020: RNAimmune venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs